Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 good response randomized controlled trial Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Bone Neoplasms
  • Neoadjuvant Therapy
  • Osteosarcoma
  • Osteotomy

abstract

  • At the preplanned analysis time, MAP plus IFN-α-2b was not statistically different from MAP alone. A considerable proportion of patients never started IFN-α-2b or stopped prematurely. Long-term follow-up for events and survival continues.

authors

publication date

  • July 10, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4486345

Digital Object Identifier (DOI)

  • 10.1200/JCO.2014.60.0734

PubMed ID

  • 26033801

Additional Document Info

start page

  • 2279

end page

  • 87

volume

  • 33

number

  • 20